Asmacure has completed dosing in a Phase II trial evaluating its lead compound, ASM-024, in moderate asthma patients, with data anticipated in 1Q14. The company also has begun patient enrollment in a Phase II trial of ASM-024 in patients with moderate and severe chronic obstructive pulmonary disease (COPD). The recently completed asthma trial is a randomized, double-blind, placebo-controlled study with a primary outcome designed to evaluate the safety, tolerability, and dose selection of the AS...